JP2020536549A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020536549A5 JP2020536549A5 JP2020520212A JP2020520212A JP2020536549A5 JP 2020536549 A5 JP2020536549 A5 JP 2020536549A5 JP 2020520212 A JP2020520212 A JP 2020520212A JP 2020520212 A JP2020520212 A JP 2020520212A JP 2020536549 A5 JP2020536549 A5 JP 2020536549A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- baa
- cancer
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 88
- -1 April Proteins 0.000 claims 31
- 239000000758 substrate Substances 0.000 claims 18
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 102000035195 Peptidases Human genes 0.000 claims 12
- 108091005804 Peptidases Proteins 0.000 claims 12
- 239000004365 Protease Substances 0.000 claims 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 12
- 230000000873 masking effect Effects 0.000 claims 12
- 229920001184 polypeptide Polymers 0.000 claims 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims 12
- 238000006467 substitution reaction Methods 0.000 claims 12
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 10
- 238000000034 method Methods 0.000 claims 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 9
- 102000001301 EGF receptor Human genes 0.000 claims 9
- 108060006698 EGF receptor Proteins 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 9
- 239000012636 effector Substances 0.000 claims 9
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims 8
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 102000005962 receptors Human genes 0.000 claims 8
- 108020003175 receptors Proteins 0.000 claims 8
- 239000013598 vector Substances 0.000 claims 8
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims 6
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims 6
- 108010022999 Serine Proteases Proteins 0.000 claims 6
- 102000012479 Serine Proteases Human genes 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 5
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims 5
- 102100023123 Mucin-16 Human genes 0.000 claims 5
- 102100027221 CD81 antigen Human genes 0.000 claims 4
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims 4
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 claims 4
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 4
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 4
- 102100022337 Integrin alpha-V Human genes 0.000 claims 4
- 108010041012 Integrin alpha4 Proteins 0.000 claims 4
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 210000001519 tissue Anatomy 0.000 claims 4
- 102100026234 Cytokine receptor common subunit gamma Human genes 0.000 claims 3
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims 3
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims 3
- 102100025306 Integrin alpha-IIb Human genes 0.000 claims 3
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims 3
- 230000003213 activating effect Effects 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 2
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 claims 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 2
- 102100028163 ATP-binding cassette sub-family C member 4 Human genes 0.000 claims 2
- 206010061424 Anal cancer Diseases 0.000 claims 2
- 102100031936 Anterior gradient protein 2 homolog Human genes 0.000 claims 2
- 208000007860 Anus Neoplasms Diseases 0.000 claims 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 2
- 208000005440 Basal Cell Neoplasms Diseases 0.000 claims 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 2
- 108010081589 Becaplermin Proteins 0.000 claims 2
- 206010005949 Bone cancer Diseases 0.000 claims 2
- 208000018084 Bone neoplasm Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 claims 2
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 claims 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims 2
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims 2
- 102100025277 C-X-C motif chemokine 13 Human genes 0.000 claims 2
- 108010008629 CA-125 Antigen Proteins 0.000 claims 2
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims 2
- 102100031171 CCN family member 1 Human genes 0.000 claims 2
- 102100031168 CCN family member 2 Human genes 0.000 claims 2
- 102100031173 CCN family member 4 Human genes 0.000 claims 2
- 101710137353 CCN family member 4 Proteins 0.000 claims 2
- 102100024210 CD166 antigen Human genes 0.000 claims 2
- 102100027207 CD27 antigen Human genes 0.000 claims 2
- 108010029697 CD40 Ligand Proteins 0.000 claims 2
- 101150013553 CD40 gene Proteins 0.000 claims 2
- 102100032937 CD40 ligand Human genes 0.000 claims 2
- 102100032912 CD44 antigen Human genes 0.000 claims 2
- 108010065524 CD52 Antigen Proteins 0.000 claims 2
- 102100025221 CD70 antigen Human genes 0.000 claims 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 2
- 102100029756 Cadherin-6 Human genes 0.000 claims 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 2
- 102100025473 Carcinoembryonic antigen-related cell adhesion molecule 6 Human genes 0.000 claims 2
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 claims 2
- 102100025175 Cellular communication network factor 6 Human genes 0.000 claims 2
- 101710118748 Cellular communication network factor 6 Proteins 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 102100039496 Choline transporter-like protein 4 Human genes 0.000 claims 2
- 102100038423 Claudin-3 Human genes 0.000 claims 2
- 108090000599 Claudin-3 Proteins 0.000 claims 2
- 102100038447 Claudin-4 Human genes 0.000 claims 2
- 108090000601 Claudin-4 Proteins 0.000 claims 2
- 102000008186 Collagen Human genes 0.000 claims 2
- 108010035532 Collagen Proteins 0.000 claims 2
- 108010019961 Cysteine-Rich Protein 61 Proteins 0.000 claims 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 2
- 102100033553 Delta-like protein 4 Human genes 0.000 claims 2
- 102100034579 Desmoglein-1 Human genes 0.000 claims 2
- 101150076616 EPHA2 gene Proteins 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 claims 2
- 102100021451 Endoplasmic reticulum chaperone BiP Human genes 0.000 claims 2
- 102100038083 Endosialin Human genes 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 2
- 102100037680 Fibroblast growth factor 8 Human genes 0.000 claims 2
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 claims 2
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 claims 2
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 claims 2
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 claims 2
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims 2
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims 2
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 claims 2
- 102100040583 Galactosylceramide sulfotransferase Human genes 0.000 claims 2
- 101710088083 Glomulin Proteins 0.000 claims 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 2
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 claims 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 2
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims 2
- 101150112743 HSPA5 gene Proteins 0.000 claims 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 2
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims 2
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 2
- 101000986629 Homo sapiens ATP-binding cassette sub-family C member 4 Proteins 0.000 claims 2
- 101000775021 Homo sapiens Anterior gradient protein 2 homolog Proteins 0.000 claims 2
- 101000952934 Homo sapiens Atrial natriuretic peptide-converting enzyme Proteins 0.000 claims 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 2
- 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 claims 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims 2
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims 2
- 101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 claims 2
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 claims 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims 2
- 101000794604 Homo sapiens Cadherin-6 Proteins 0.000 claims 2
- 101000914326 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 6 Proteins 0.000 claims 2
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 claims 2
- 101000872077 Homo sapiens Delta-like protein 4 Proteins 0.000 claims 2
- 101000924316 Homo sapiens Desmoglein-1 Proteins 0.000 claims 2
- 101000884275 Homo sapiens Endosialin Proteins 0.000 claims 2
- 101001027382 Homo sapiens Fibroblast growth factor 8 Proteins 0.000 claims 2
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 claims 2
- 101000893879 Homo sapiens Galactosylceramide sulfotransferase Proteins 0.000 claims 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 2
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims 2
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims 2
- 101100232357 Homo sapiens IL13RA1 gene Proteins 0.000 claims 2
- 101100232360 Homo sapiens IL13RA2 gene Proteins 0.000 claims 2
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims 2
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 claims 2
- 101001046677 Homo sapiens Integrin alpha-V Proteins 0.000 claims 2
- 101001002470 Homo sapiens Interferon lambda-1 Proteins 0.000 claims 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 2
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 claims 2
- 101001076418 Homo sapiens Interleukin-1 receptor type 1 Proteins 0.000 claims 2
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 claims 2
- 101000853012 Homo sapiens Interleukin-23 receptor Proteins 0.000 claims 2
- 101001043821 Homo sapiens Interleukin-31 Proteins 0.000 claims 2
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 claims 2
- 101001004865 Homo sapiens Leucine-rich repeat-containing protein 26 Proteins 0.000 claims 2
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims 2
- 101001043598 Homo sapiens Low-density lipoprotein receptor-related protein 4 Proteins 0.000 claims 2
- 101000694615 Homo sapiens Membrane primary amine oxidase Proteins 0.000 claims 2
- 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 claims 2
- 101000628535 Homo sapiens Metalloreductase STEAP2 Proteins 0.000 claims 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 2
- 101000603877 Homo sapiens Nuclear receptor subfamily 1 group I member 2 Proteins 0.000 claims 2
- 101000897042 Homo sapiens Nucleotide pyrophosphatase Proteins 0.000 claims 2
- 101000829725 Homo sapiens Phospholipid hydroperoxide glutathione peroxidase Proteins 0.000 claims 2
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 claims 2
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims 2
- 101000928535 Homo sapiens Protein delta homolog 1 Proteins 0.000 claims 2
- 101001098560 Homo sapiens Proteinase-activated receptor 2 Proteins 0.000 claims 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 2
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims 2
- 101000713170 Homo sapiens Solute carrier family 52, riboflavin transporter, member 1 Proteins 0.000 claims 2
- 101001056234 Homo sapiens Sperm mitochondrial-associated cysteine-rich protein Proteins 0.000 claims 2
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 2
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 claims 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims 2
- 101000669406 Homo sapiens Toll-like receptor 6 Proteins 0.000 claims 2
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims 2
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 claims 2
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 claims 2
- 101000904724 Homo sapiens Transmembrane glycoprotein NMB Proteins 0.000 claims 2
- 101000798694 Homo sapiens Transmembrane protein 31 Proteins 0.000 claims 2
- 101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 claims 2
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 claims 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 2
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 claims 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 2
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims 2
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 claims 2
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims 2
- 101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 claims 2
- 108010003272 Hyaluronate lyase Proteins 0.000 claims 2
- 102000001974 Hyaluronidases Human genes 0.000 claims 2
- 102000026633 IL6 Human genes 0.000 claims 2
- 102000009438 IgE Receptors Human genes 0.000 claims 2
- 108010073816 IgE Receptors Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 108010001127 Insulin Receptor Proteins 0.000 claims 2
- 102100036721 Insulin receptor Human genes 0.000 claims 2
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims 2
- 108010008212 Integrin alpha4beta1 Proteins 0.000 claims 2
- 102000012355 Integrin beta1 Human genes 0.000 claims 2
- 102100020990 Interferon lambda-1 Human genes 0.000 claims 2
- 102100039065 Interleukin-1 beta Human genes 0.000 claims 2
- 102100026016 Interleukin-1 receptor type 1 Human genes 0.000 claims 2
- 102000003815 Interleukin-11 Human genes 0.000 claims 2
- 108090000177 Interleukin-11 Proteins 0.000 claims 2
- 102000013462 Interleukin-12 Human genes 0.000 claims 2
- 108010065805 Interleukin-12 Proteins 0.000 claims 2
- 102100020790 Interleukin-12 receptor subunit beta-1 Human genes 0.000 claims 2
- 101710103841 Interleukin-12 receptor subunit beta-1 Proteins 0.000 claims 2
- 108090000176 Interleukin-13 Proteins 0.000 claims 2
- 102000003816 Interleukin-13 Human genes 0.000 claims 2
- 102100020791 Interleukin-13 receptor subunit alpha-1 Human genes 0.000 claims 2
- 108090000172 Interleukin-15 Proteins 0.000 claims 2
- 102000003812 Interleukin-15 Human genes 0.000 claims 2
- 102100033461 Interleukin-17A Human genes 0.000 claims 2
- 102000003810 Interleukin-18 Human genes 0.000 claims 2
- 108090000171 Interleukin-18 Proteins 0.000 claims 2
- 102000000588 Interleukin-2 Human genes 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 102100030704 Interleukin-21 Human genes 0.000 claims 2
- 108010065637 Interleukin-23 Proteins 0.000 claims 2
- 102000013264 Interleukin-23 Human genes 0.000 claims 2
- 102100036672 Interleukin-23 receptor Human genes 0.000 claims 2
- 108010066979 Interleukin-27 Proteins 0.000 claims 2
- 102100036678 Interleukin-27 subunit alpha Human genes 0.000 claims 2
- 102100021596 Interleukin-31 Human genes 0.000 claims 2
- 102000004388 Interleukin-4 Human genes 0.000 claims 2
- 108090000978 Interleukin-4 Proteins 0.000 claims 2
- 102100039881 Interleukin-5 receptor subunit alpha Human genes 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims 2
- 108010018951 Interleukin-8B Receptors Proteins 0.000 claims 2
- 108700003486 Jagged-1 Proteins 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 102000017578 LAG3 Human genes 0.000 claims 2
- 101150030213 Lag3 gene Proteins 0.000 claims 2
- 102100025950 Leucine-rich repeat-containing protein 26 Human genes 0.000 claims 2
- 102100021747 Leukemia inhibitory factor receptor Human genes 0.000 claims 2
- 101710142062 Leukemia inhibitory factor receptor Proteins 0.000 claims 2
- 108010028275 Leukocyte Elastase Proteins 0.000 claims 2
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims 2
- 102100021918 Low-density lipoprotein receptor-related protein 4 Human genes 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 claims 2
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 2
- 102100027159 Membrane primary amine oxidase Human genes 0.000 claims 2
- 102100026712 Metalloreductase STEAP1 Human genes 0.000 claims 2
- 102100026711 Metalloreductase STEAP2 Human genes 0.000 claims 2
- 102100034256 Mucin-1 Human genes 0.000 claims 2
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 2
- 101100369076 Mus musculus Tdgf1 gene Proteins 0.000 claims 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 2
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 claims 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 2
- 102100033174 Neutrophil elastase Human genes 0.000 claims 2
- 108010070047 Notch Receptors Proteins 0.000 claims 2
- 102000005650 Notch Receptors Human genes 0.000 claims 2
- 102100021969 Nucleotide pyrophosphatase Human genes 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 claims 2
- 102000018967 Platelet-Derived Growth Factor beta Receptor Human genes 0.000 claims 2
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims 2
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 2
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 2
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 102100036467 Protein delta homolog 1 Human genes 0.000 claims 2
- 102100032702 Protein jagged-1 Human genes 0.000 claims 2
- 108700037966 Protein jagged-1 Proteins 0.000 claims 2
- 102100032733 Protein jagged-2 Human genes 0.000 claims 2
- 101710170213 Protein jagged-2 Proteins 0.000 claims 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 2
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 2
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 108091006296 SLC2A1 Proteins 0.000 claims 2
- 108091006300 SLC2A4 Proteins 0.000 claims 2
- 108091007561 SLC44A4 Proteins 0.000 claims 2
- 101100111629 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) KAR2 gene Proteins 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 102100038081 Signal transducer CD24 Human genes 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 102100023536 Solute carrier family 2, facilitated glucose transporter member 1 Human genes 0.000 claims 2
- 102100033939 Solute carrier family 2, facilitated glucose transporter member 4 Human genes 0.000 claims 2
- 102100036863 Solute carrier family 52, riboflavin transporter, member 1 Human genes 0.000 claims 2
- 102100026503 Sperm mitochondrial-associated cysteine-rich protein Human genes 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 2
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims 2
- 102100024333 Toll-like receptor 2 Human genes 0.000 claims 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims 2
- 102100039387 Toll-like receptor 6 Human genes 0.000 claims 2
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims 2
- 102100033110 Toll-like receptor 8 Human genes 0.000 claims 2
- 102100033117 Toll-like receptor 9 Human genes 0.000 claims 2
- 102000004357 Transferases Human genes 0.000 claims 2
- 108090000992 Transferases Proteins 0.000 claims 2
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 claims 2
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 claims 2
- 102100032456 Transmembrane protein 31 Human genes 0.000 claims 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 2
- 101710181056 Tumor necrosis factor ligand superfamily member 13B Proteins 0.000 claims 2
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 claims 2
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 claims 2
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 claims 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 2
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 claims 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims 2
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims 2
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims 2
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 claims 2
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 claims 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 2
- 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 claims 2
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 claims 2
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 claims 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 2
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 claims 2
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 claims 2
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 claims 2
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 claims 2
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 2
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 claims 2
- DUKURNFHYQXCJG-JEOLMMCMSA-N alpha-L-Fucp-(1->4)-[beta-D-Galp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](NC(C)=O)[C@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H](OC(O)[C@H](O)[C@H]3O)CO)O[C@H](CO)[C@@H]2O)O)O[C@@H]1CO DUKURNFHYQXCJG-JEOLMMCMSA-N 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 201000011165 anus cancer Diseases 0.000 claims 2
- 210000000941 bile Anatomy 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 229920001436 collagen Polymers 0.000 claims 2
- 230000018044 dehydration Effects 0.000 claims 2
- 238000006297 dehydration reaction Methods 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 229940088598 enzyme Drugs 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims 2
- 102000006815 folate receptor Human genes 0.000 claims 2
- 108020005243 folate receptor Proteins 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 101150028578 grp78 gene Proteins 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 229960002773 hyaluronidase Drugs 0.000 claims 2
- 239000012642 immune effector Substances 0.000 claims 2
- 229940121354 immunomodulator Drugs 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 108010021315 integrin beta7 Proteins 0.000 claims 2
- 108040003610 interleukin-12 receptor activity proteins Proteins 0.000 claims 2
- 108010074108 interleukin-21 Proteins 0.000 claims 2
- 201000002313 intestinal cancer Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 102000046701 nicastrin Human genes 0.000 claims 2
- 108700022821 nicastrin Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 108010017843 platelet-derived growth factor A Proteins 0.000 claims 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 101150047061 tag-72 gene Proteins 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 2
- 102000009816 urokinase plasminogen activator receptor activity proteins Human genes 0.000 claims 2
- 108040001269 urokinase plasminogen activator receptor activity proteins Proteins 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 102100025215 CCN family member 5 Human genes 0.000 claims 1
- 101710137354 CCN family member 5 Proteins 0.000 claims 1
- 108010058905 CD44v6 antigen Proteins 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 108010028773 Complement C5 Proteins 0.000 claims 1
- 101710189311 Cytokine receptor common subunit gamma Proteins 0.000 claims 1
- 101150097734 EPHB2 gene Proteins 0.000 claims 1
- 102100031968 Ephrin type-B receptor 2 Human genes 0.000 claims 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims 1
- 101001033312 Homo sapiens Interleukin-4 receptor subunit alpha Proteins 0.000 claims 1
- 101710149643 Integrin alpha-IIb Proteins 0.000 claims 1
- 102100039078 Interleukin-4 receptor subunit alpha Human genes 0.000 claims 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims 1
- 102000003735 Mesothelin Human genes 0.000 claims 1
- 108090000015 Mesothelin Proteins 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 108010035030 Platelet Membrane Glycoprotein IIb Proteins 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 201000009036 biliary tract cancer Diseases 0.000 claims 1
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 230000000112 colonic effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000001934 delay Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000014899 intrahepatic bile duct cancer Diseases 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 claims 1
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023176130A JP7840916B2 (ja) | 2017-10-14 | 2023-10-11 | 抗体、活性化可能抗体、二重特異性抗体、および二重特異性活性化可能抗体ならびにその使用方法 |
| JP2025135273A JP2025175286A (ja) | 2017-10-14 | 2025-08-14 | 抗体、活性化可能抗体、二重特異性抗体、および二重特異性活性化可能抗体ならびにその使用方法 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762572468P | 2017-10-14 | 2017-10-14 | |
| US62/572,468 | 2017-10-14 | ||
| US201762577140P | 2017-10-25 | 2017-10-25 | |
| US62/577,140 | 2017-10-25 | ||
| US201862613358P | 2018-01-03 | 2018-01-03 | |
| US62/613,358 | 2018-01-03 | ||
| US201862666065P | 2018-05-02 | 2018-05-02 | |
| US62/666,065 | 2018-05-02 | ||
| US201862731622P | 2018-09-14 | 2018-09-14 | |
| US62/731,622 | 2018-09-14 | ||
| PCT/US2018/055717 WO2019075405A1 (en) | 2017-10-14 | 2018-10-12 | ANTIBODIES, ACTIVISTIC ANTIBODIES, BISPECIFIC ANTIBODIES, AND BISPECIFICALLY ACTIVATED ANTIBODIES AND METHODS OF USE THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023176130A Division JP7840916B2 (ja) | 2017-10-14 | 2023-10-11 | 抗体、活性化可能抗体、二重特異性抗体、および二重特異性活性化可能抗体ならびにその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020536549A JP2020536549A (ja) | 2020-12-17 |
| JP2020536549A5 true JP2020536549A5 (https=) | 2021-11-11 |
| JP7438106B2 JP7438106B2 (ja) | 2024-02-26 |
Family
ID=64308799
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020520212A Active JP7438106B2 (ja) | 2017-10-14 | 2018-10-12 | 抗体、活性化可能抗体、二重特異性抗体、および二重特異性活性化可能抗体ならびにその使用方法 |
| JP2023176130A Active JP7840916B2 (ja) | 2017-10-14 | 2023-10-11 | 抗体、活性化可能抗体、二重特異性抗体、および二重特異性活性化可能抗体ならびにその使用方法 |
| JP2025135273A Pending JP2025175286A (ja) | 2017-10-14 | 2025-08-14 | 抗体、活性化可能抗体、二重特異性抗体、および二重特異性活性化可能抗体ならびにその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023176130A Active JP7840916B2 (ja) | 2017-10-14 | 2023-10-11 | 抗体、活性化可能抗体、二重特異性抗体、および二重特異性活性化可能抗体ならびにその使用方法 |
| JP2025135273A Pending JP2025175286A (ja) | 2017-10-14 | 2025-08-14 | 抗体、活性化可能抗体、二重特異性抗体、および二重特異性活性化可能抗体ならびにその使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11472889B2 (https=) |
| EP (1) | EP3694885A1 (https=) |
| JP (3) | JP7438106B2 (https=) |
| KR (1) | KR20200064096A (https=) |
| CN (1) | CN111247171A (https=) |
| AU (1) | AU2018347607B2 (https=) |
| BR (1) | BR112020007309A2 (https=) |
| CA (2) | CA3287794A1 (https=) |
| IL (2) | IL321773A (https=) |
| SG (1) | SG11202002384VA (https=) |
| TW (1) | TWI850203B (https=) |
| WO (1) | WO2019075405A1 (https=) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105722859B (zh) | 2013-07-25 | 2021-05-07 | 西托姆克斯治疗公司 | 多特异性抗体、多特异性可活化抗体及其使用方法 |
| JP7020909B2 (ja) | 2014-07-25 | 2022-02-16 | シトムクス セラピューティクス，インコーポレイティド | 抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法 |
| CA3287794A1 (en) * | 2017-10-14 | 2025-10-27 | Cytomx Therapeutics, Inc. | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof |
| TW202014436A (zh) * | 2018-05-02 | 2020-04-16 | 美商Ｃｙｔｏｍｘ生物製藥公司 | 抗體、可活化之抗體、雙特異性抗體、及雙特異性可活化之抗體及使用彼之方法 |
| AU2019271148B9 (en) | 2018-05-14 | 2025-05-29 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
| CA3100005A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| US12534734B2 (en) * | 2018-05-15 | 2026-01-27 | Drive Therapeutics Llc | Stem-loop compositions and methods for inhibiting interleukin-8 |
| KR20220023988A (ko) | 2019-05-14 | 2022-03-03 | 웨어울프 세라퓨틱스, 인크. | 분리 모이어티 및 이의 사용 방법 |
| CN114423499A (zh) * | 2019-06-06 | 2022-04-29 | 佳努克斯治疗公司 | 与肿瘤激活的t细胞衔接子相关的组合物和方法 |
| US20220289822A1 (en) * | 2019-08-21 | 2022-09-15 | AskGene Pharma, Inc. | Novel il-21 prodrugs and methods of use thereof |
| KR20220071263A (ko) * | 2019-09-30 | 2022-05-31 | 하버 바이오메드 (쑤저우) 컴퍼니 리미티드 | Cd3을 표적으로 하는 항체, 이중 특이성 항체 및 이의 용도 |
| BR112022009110A2 (pt) | 2019-11-14 | 2022-07-26 | Werewolf Therapeutics Inc | Polipeptídeos de citocina ativáveis e métodos de uso destes |
| AU2021254283B2 (en) | 2020-04-10 | 2025-12-11 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| US20230322953A1 (en) * | 2020-06-30 | 2023-10-12 | Harbour Biomed (Shanghai) Co., Ltd | Binding protein having h2l2 and hcab structures |
| WO2022035866A1 (en) | 2020-08-11 | 2022-02-17 | Janux Therapeutics, Inc. | Cleavable linker compositions and methods |
| KR20230079165A (ko) * | 2020-09-29 | 2023-06-05 | 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 | 항-클라우딘18.2 및 cd3 이특이적 항체 및 이의 용도 |
| EP4247850A1 (en) | 2020-11-20 | 2023-09-27 | Simcere Innovation, Inc. | Armed dual car-t compositions and methods for cancer immunotherapy |
| US20240301086A1 (en) * | 2020-12-01 | 2024-09-12 | Aptevo Research And Development Llc | Tumor-associated antigens and cd3-binding proteins, related compositions, and methods |
| AU2021396172A1 (en) | 2020-12-09 | 2023-07-06 | Janux Therapeutics, Inc. | Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens |
| WO2022135536A1 (zh) * | 2020-12-25 | 2022-06-30 | 江苏先声药业有限公司 | Cd3人源化抗体及其应用 |
| WO2022170619A1 (en) * | 2021-02-11 | 2022-08-18 | Adagene Pte. Ltd. | Anti-cd3 antibodies and methods of use thereof |
| JP2024511387A (ja) * | 2021-03-16 | 2024-03-13 | シートムエックス セラピューティクス，インコーポレイテッド | マスクした活性化可能サイトカイン構成体ならびに関連する組成物及び方法 |
| AU2022341443A1 (en) * | 2021-09-13 | 2024-03-28 | Shandong Simcere Zaiming Biopharmaceutical Co., Ltd. | Anti-human cd3 antibody and use thereof |
| JP2024539650A (ja) * | 2021-10-15 | 2024-10-29 | シートムエックス セラピューティクス，インコーポレイテッド | 活性化可能なポリペプチド複合体 |
| WO2023064955A1 (en) | 2021-10-15 | 2023-04-20 | Cytomx Therapeutics, Inc. | Activatable anti-cd3, anti-egfr, heteromultimeric bispecific polypeptide complex |
| AU2022367525A1 (en) | 2021-10-15 | 2024-05-02 | Amgen Inc. | Activatable polypeptide complex |
| CN113980143B (zh) * | 2021-11-02 | 2023-04-25 | 深圳先进技术研究院 | 靶向cd276的嵌合抗原受体、嵌合抗原受体t细胞及制备方法和制药应用 |
| WO2023148388A1 (en) * | 2022-02-04 | 2023-08-10 | Zytox Therapeutics Ab | Fusion protein comprising an egfr-binding domain and a masking domain |
| WO2023183888A1 (en) | 2022-03-23 | 2023-09-28 | Cytomx Therapeutics, Inc. | Activatable antigen-binding protein constructs and uses of the same |
| US20250333487A1 (en) | 2022-03-25 | 2025-10-30 | Cytomx Therapeutics, Inc. | Activatable dual-anchored masked molecules and methods of use thereof |
| JP2025511187A (ja) | 2022-04-01 | 2025-04-15 | サイトムエックス セラピューティクス，インク． | Ｃｄ３結合タンパク質及びその使用方法 |
| WO2023192973A1 (en) | 2022-04-01 | 2023-10-05 | Cytomx Therapeutics, Inc. | Activatable multispecific molecules and methods of use thereof |
| US20260042849A1 (en) | 2022-08-01 | 2026-02-12 | Cytomx Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
| JP2025525879A (ja) | 2022-08-01 | 2025-08-07 | サイトムエックス セラピューティクス，インク． | プロテアーゼ切断性基質及びその使用方法 |
| AR130079A1 (es) | 2022-08-01 | 2024-10-30 | Cytomx Therapeutics Inc | Restos escindibles por proteasas, y métodos de uso de los mismos |
| JP2025525868A (ja) | 2022-08-01 | 2025-08-07 | サイトムエックス セラピューティクス，インク． | プロテアーゼ切断性部分及びその使用方法 |
| TW202424183A (zh) | 2022-08-01 | 2024-06-16 | 美商Ｃｙｔｏｍｘ生物製藥公司 | 蛋白酶可切割受質及其使用方法 |
| EP4619427A1 (en) * | 2022-11-15 | 2025-09-24 | F. Hoffmann-La Roche AG | Recombinant binding proteins with activatable effector domain |
| EP4695281A1 (en) | 2023-04-12 | 2026-02-18 | CytomX Therapeutics, Inc. | Masking polypeptides, activatable cytokine constructs, and related compositions and methods |
| WO2024216146A1 (en) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Masking polypeptides, activatable cytokine constructs, and related compositions and methods |
| WO2024216170A2 (en) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| WO2025235515A1 (en) | 2024-05-07 | 2025-11-13 | Cytomx Therapeutics, Inc. | Activatable polypeptide complex formulations |
| WO2025240659A2 (en) | 2024-05-14 | 2025-11-20 | Cytomx Therapeutics, Inc. | Activatable constructs, compositions and methods |
| WO2025237931A1 (en) * | 2024-05-15 | 2025-11-20 | F. Hoffmann-La Roche Ag | Recombinant binding proteins with conditionally activatable t cell and nk cell recruiting effector domains |
| WO2025240781A2 (en) * | 2024-05-15 | 2025-11-20 | Werewolf Therapeutics, Inc. | Modified antibodies and immunoglobulin formats |
| WO2026002279A1 (en) * | 2024-06-28 | 2026-01-02 | Vibrant Pharma Limited | Mask peptide, cleavable substrate, multispecific antibodies and uses thereof |
| WO2026020161A1 (en) | 2024-07-19 | 2026-01-22 | Cytomx Therapeutics, Inc. | Activatable il-12 constructs and related compositions and methods |
| WO2026024841A1 (en) | 2024-07-24 | 2026-01-29 | Astellas Us Llc | Bispecific antibodies that bind cd3 and muc1 and methods of use thereof |
| WO2026035650A2 (en) | 2024-08-05 | 2026-02-12 | Cytomx Therapeutics, Inc. | Cleavable polypeptides and methods of use thereof |
Family Cites Families (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| DE3788058T2 (de) | 1986-08-28 | 1994-04-21 | Teijin Ltd | Zelltoxischer antikörperkomplex und verfahren zu seiner herstellung. |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| MD1367C2 (ro) | 1992-11-13 | 2000-11-30 | Idec Pharmaceuticals Corporation | Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom. |
| IT1271461B (it) | 1993-12-01 | 1997-05-28 | Menarini Ricerche Sud Spa | Anticorpo monoclonale bispecifico anti-cd3/anti-egfr,processo per la produzione e suo uso. |
| US20030105294A1 (en) | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
| CZ20003099A3 (cs) | 1998-02-25 | 2002-04-17 | Lexigen Pharmaceuticals Corporation | Zvýąení doby poloviční ľivotnosti cirkulujících fúzních proteinů odvozených od protilátek |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| CZ302070B6 (cs) | 1998-04-21 | 2010-09-29 | Micromet Ag | Jednoretezcový multifunkcní polypeptid, polynukleotid, vektor obsahující tento polynukleotid, bunka transfekovaná tímto polynukleotidem, prostredek obsahující tento polypeptid, polynukleotid nebo vektor a jejich použití a zpusob identifikace aktiváto |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| HU230769B1 (hu) | 1999-01-15 | 2018-03-28 | Genentech Inc. | Módosított effektor-funkciójú polipeptid-változatok |
| HUP0204475A2 (en) | 2000-02-11 | 2003-04-28 | Merck Patent Gmbh | Enhancing the circulating half-life of antibody-based fusion proteins |
| WO2001091798A2 (en) | 2000-06-01 | 2001-12-06 | Universite Catholique De Louvain | Tumor activated prodrug compounds |
| ATE513563T1 (de) | 2000-10-09 | 2011-07-15 | Isis Innovation | Therapeutische und toleranz-induzierende antikörper |
| US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
| US20030150294A1 (en) | 2002-01-25 | 2003-08-14 | Njall Stefansson | Filters for filtering molten metals and alloys field |
| ES2263984T3 (es) | 2002-06-28 | 2006-12-16 | Domantis Limited | Ligandos doble-especificos con una vida media serica aumentada. |
| US20040109855A1 (en) | 2002-07-23 | 2004-06-10 | Herman Waldmann | Therapeutic antibodies with reduced side effect |
| US8809504B2 (en) | 2002-09-03 | 2014-08-19 | Vit Lauermann | Inhibitor which is deactivatable by a reagent produced by a target cell |
| DE602004023956D1 (de) | 2003-08-18 | 2009-12-17 | Univ California | Polypeptid-display-bibliotheken und verfahren zur herstellung und verwendung davon |
| KR100891620B1 (ko) | 2004-04-13 | 2009-04-02 | 에프. 호프만-라 로슈 아게 | 항-ｐ-셀렉틴 항체 |
| JP5139800B2 (ja) | 2004-06-03 | 2013-02-06 | ノビミューン エスアー | 抗ｃｄ３抗体およびその使用方法 |
| EP2535346B1 (en) | 2005-08-31 | 2017-08-02 | The Regents of The University of California | Cellular libraries of peptide sequences (CLiPS) and methods of using the same |
| AU2006301492B2 (en) | 2005-10-11 | 2011-06-09 | Amgen Research (Munich) Gmbh | Compositions comprising cross-species-specific antibodies and uses thereof |
| JP2009529522A (ja) | 2006-03-10 | 2009-08-20 | ディアト | 酵素で切断可能なリンカーを介して抗体に複合された抗癌剤 |
| KR101516823B1 (ko) | 2006-03-17 | 2015-05-07 | 바이오겐 아이덱 엠에이 인코포레이티드 | 안정화된 폴리펩티드 조성물 |
| BRPI0713421A2 (pt) | 2006-06-14 | 2012-03-13 | Imclone Systems Incorporated | Formulação liofolizada, formulação aquosa adequada para a liofilização, e, métodos para estabilizar am anticorpo e para tratar um mamífero |
| WO2008119566A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific bispecific binders |
| RS53008B2 (sr) | 2007-04-03 | 2022-12-30 | Amgen Res Munich Gmbh | Interspecijski specifičan cd3-epsilon vezujući domen |
| TWI570135B (zh) | 2007-04-27 | 2017-02-11 | 建南德克公司 | 高效、穩定且非免疫抑制之抗－ｃｄ４抗體 |
| US8293685B2 (en) | 2007-07-26 | 2012-10-23 | The Regents Of The University Of California | Methods for enhancing bacterial cell display of proteins and peptides |
| KR20100058509A (ko) | 2007-07-31 | 2010-06-03 | 메디뮨 엘엘씨 | 다중특이적 에피토프 결합 단백질 및 이의 용도 |
| CA2697032C (en) | 2007-08-22 | 2021-09-14 | The Regents Of The University Of California | Activatable binding polypeptides and methods of identification and use thereof |
| HRP20160855T1 (hr) | 2008-02-08 | 2016-09-23 | Medimmune, Llc | Anti-ifnar1 protutijela sa smanjenim afinitetom fc liganda |
| JP6126782B2 (ja) | 2008-10-01 | 2017-05-10 | アムゲン リサーチ （ミュンヘン） ゲーエムベーハー | 異種間特異的ｐｓｍａ×ｃｄ３二重特異性単鎖抗体 |
| CA2738568C (en) | 2008-10-01 | 2024-02-20 | Micromet Ag | Cross-species-specific single domain bispecific single chain antibody |
| CN105218673A (zh) | 2008-10-10 | 2016-01-06 | 新兴产品开发西雅图有限公司 | Tcr复合物免疫治疗剂 |
| US8895702B2 (en) | 2008-12-08 | 2014-11-25 | City Of Hope | Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies |
| EP2356131A4 (en) | 2008-12-08 | 2012-09-12 | Tegopharm Corp | MASKING LIGANDS FOR REVERSIBLE INHIBITION OF VERSATILE COMPOUNDS |
| US20100189651A1 (en) | 2009-01-12 | 2010-07-29 | Cytomx Therapeutics, Llc | Modified antibody compositions, methods of making and using thereof |
| JP5861223B2 (ja) | 2009-02-23 | 2016-02-16 | サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. | プロタンパク質およびその使用方法 |
| US9309325B2 (en) | 2009-05-07 | 2016-04-12 | The Regents Of The University Of California | Antibodies and methods of use thereof |
| CA3083324A1 (en) | 2010-03-05 | 2011-09-09 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| TWI653333B (zh) | 2010-04-01 | 2019-03-11 | 安進研究（慕尼黑）有限責任公司 | 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體 |
| MX340556B (es) | 2010-08-24 | 2016-07-14 | Roche Glycart Ag | Anticuerpos biespecificos activables. |
| PH12016502073B1 (en) | 2010-11-17 | 2024-04-05 | Chugai Pharmaceutical Co Ltd | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii |
| WO2012088247A2 (en) | 2010-12-22 | 2012-06-28 | Medimmune, Llc | Anti-c5/c5a/c5adesr antibodies and fragments |
| SG10201602394QA (en) | 2011-03-29 | 2016-05-30 | Roche Glycart Ag | Antibody FC Variants |
| WO2012158818A2 (en) | 2011-05-16 | 2012-11-22 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
| DK2714733T3 (da) * | 2011-05-21 | 2019-05-06 | Macrogenics Inc | Cd3-bindende molekyler, der er i stand til at binde til human og ikke-human cd3 |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| MY169358A (en) | 2011-08-23 | 2019-03-26 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| BR112014004168A2 (pt) | 2011-08-23 | 2017-12-12 | Roche Glycart Ag | anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, célula hospedeira procariótica ou eucariótica, método de produção de anticorpo e invenção |
| WO2013026837A1 (en) | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| WO2013026835A1 (en) | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Fc-free antibodies comprising two fab fragments and methods of use |
| LT2794658T (lt) | 2011-12-19 | 2017-05-10 | Synimmune Gmbh | Bispecifinė antikūno molekulė |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| ES2637341T3 (es) | 2012-03-14 | 2017-10-11 | Levicept Ltd. | Proteína de unión a neurotrofina P75NTR para su utilización terapéutica |
| CN104540518A (zh) | 2012-04-27 | 2015-04-22 | 西托姆克斯治疗公司 | 结合表皮生长因子受体的可活化的抗体其使用方法 |
| WO2013192546A1 (en) | 2012-06-22 | 2013-12-27 | Cytomx Therapeutics, Inc. | Activatable antibodies having non-binding steric moieties and mehtods of using the same |
| MX2014016038A (es) | 2012-06-22 | 2015-08-14 | Cytomx Therapeutics Inc | Anticuerpos de reaccion cruzada anti - jagged 1 / jagged 2, anticuerpos anti - jagged activables y metodos para uso de los mismos. |
| BR112015000167B1 (pt) | 2012-07-06 | 2021-11-23 | Genmab B.V. | Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante |
| WO2014012085A2 (en) | 2012-07-13 | 2014-01-16 | Zymeworks Inc. | Bispecific asymmetric heterodimers comprising anti-cd3 constructs |
| CN104684928A (zh) | 2012-08-02 | 2015-06-03 | Jn生物科学有限责任公司 | 通过半胱氨酸突变和μ尾端多聚化的抗体或融合蛋白 |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| US9487590B2 (en) | 2012-09-25 | 2016-11-08 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind interleukin-6 receptor and methods of use thereof |
| CN104271602B (zh) * | 2012-11-21 | 2020-08-21 | 武汉友芝友生物制药有限公司 | 双特异性抗体 |
| ES2862950T3 (es) | 2012-12-18 | 2021-10-08 | Univ Rockefeller | Anticuerpos anti-CD4 modificados con glicanos para la prevención y terapia del VIH |
| CA2896282C (en) | 2013-01-04 | 2021-07-20 | Cytomx Therapeutics, Inc. | Compositions and methods for detecting protease activity in biological systems |
| CA2898100C (en) | 2013-01-14 | 2023-10-10 | Xencor, Inc. | Novel heterodimeric proteins |
| US9738722B2 (en) | 2013-01-15 | 2017-08-22 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
| AU2014236769B2 (en) | 2013-03-15 | 2018-09-27 | Amgen Inc. | Heterodimeric bispecific antibodies |
| US20140308285A1 (en) | 2013-03-15 | 2014-10-16 | Amgen Inc. | Heterodimeric bispecific antibodies |
| US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| WO2014186842A1 (en) | 2013-05-22 | 2014-11-27 | Monash University | Antibodies and uses thereof |
| US9517276B2 (en) | 2013-06-04 | 2016-12-13 | Cytomx Therapeutics, Inc. | Compositions and methods for conjugating activatable antibodies |
| MX373245B (es) | 2013-07-05 | 2020-05-11 | Genmab As | Anticuerpos cd3 humanizados o quiméricos. |
| TR201904121T4 (tr) | 2013-07-09 | 2019-04-22 | The Government Of The United States As Represented By The Secretary Of The Dept Of Health And Human | İnsan bispesifik egfrviii antikoru birleştirme molekülleri. |
| CN105722859B (zh) | 2013-07-25 | 2021-05-07 | 西托姆克斯治疗公司 | 多特异性抗体、多特异性可活化抗体及其使用方法 |
| CN105764501A (zh) | 2013-07-26 | 2016-07-13 | 现代化制药公司 | 改善比生群治疗效益的组合物 |
| EP3733710A1 (en) | 2013-09-25 | 2020-11-04 | Amgen, Inc | Hetrodimeric v-c-fc-v-c antibody |
| WO2015066279A2 (en) | 2013-10-30 | 2015-05-07 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
| IL270562B (en) | 2014-01-31 | 2022-08-01 | Cytomx Therapeutics Inc | Polypeptide substrates that activate matriptase and u-plasminogen and other cleavable groups, preparations containing them and their uses |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| US9212225B1 (en) | 2014-07-01 | 2015-12-15 | Amphivena Therapeutics, Inc. | Bispecific CD33 and CD3 binding proteins |
| JP7020909B2 (ja) | 2014-07-25 | 2022-02-16 | シトムクス セラピューティクス，インコーポレイティド | 抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法 |
| AU2015323313B2 (en) | 2014-09-25 | 2021-04-01 | Amgen Inc. | Protease-activatable bispecific proteins |
| MA40894A (fr) | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
| CN110894240B (zh) | 2014-11-26 | 2022-04-15 | 森科股份有限公司 | 结合cd3和肿瘤抗原的异二聚体抗体 |
| MA41374A (fr) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| CR20170383A (es) | 2015-01-23 | 2017-11-22 | Sanofi Sa | Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 |
| AU2016246695A1 (en) | 2015-04-07 | 2017-10-26 | Genentech, Inc. | Antigen binding complex having agonistic activity and methods of use |
| BR112017023862A2 (pt) | 2015-05-04 | 2018-07-17 | Cytomx Therapeutics Inc | anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes |
| EA039859B1 (ru) | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| CN109476756B (zh) * | 2016-03-15 | 2022-05-31 | 埃泰美德(香港)有限公司 | 一种多特异性Fab融合蛋白及其用途 |
| CR20180453A (es) | 2016-03-22 | 2018-12-05 | Hoffmann La Roche | Moleculas biespecíficas de células t activadas por proteasas |
| CA3287794A1 (en) * | 2017-10-14 | 2025-10-27 | Cytomx Therapeutics, Inc. | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof |
| TW202014436A (zh) | 2018-05-02 | 2020-04-16 | 美商Ｃｙｔｏｍｘ生物製藥公司 | 抗體、可活化之抗體、雙特異性抗體、及雙特異性可活化之抗體及使用彼之方法 |
| WO2022035866A1 (en) * | 2020-08-11 | 2022-02-17 | Janux Therapeutics, Inc. | Cleavable linker compositions and methods |
| CN114085290A (zh) | 2020-08-25 | 2022-02-25 | 泰州迈博太科药业有限公司 | 一种抗体前体药物、其制备方法及应用 |
-
2018
- 2018-10-12 CA CA3287794A patent/CA3287794A1/en active Pending
- 2018-10-12 WO PCT/US2018/055717 patent/WO2019075405A1/en not_active Ceased
- 2018-10-12 JP JP2020520212A patent/JP7438106B2/ja active Active
- 2018-10-12 IL IL321773A patent/IL321773A/en unknown
- 2018-10-12 BR BR112020007309-1A patent/BR112020007309A2/pt not_active Application Discontinuation
- 2018-10-12 KR KR1020207011417A patent/KR20200064096A/ko not_active Ceased
- 2018-10-12 AU AU2018347607A patent/AU2018347607B2/en active Active
- 2018-10-12 SG SG11202002384VA patent/SG11202002384VA/en unknown
- 2018-10-12 CA CA3078911A patent/CA3078911C/en active Active
- 2018-10-12 IL IL273937A patent/IL273937B2/en unknown
- 2018-10-12 EP EP18803495.3A patent/EP3694885A1/en active Pending
- 2018-10-12 TW TW107136021A patent/TWI850203B/zh active
- 2018-10-12 CN CN201880068235.0A patent/CN111247171A/zh active Pending
- 2018-10-12 US US16/159,451 patent/US11472889B2/en active Active
-
2022
- 2022-09-07 US US17/930,143 patent/US11859010B2/en active Active
-
2023
- 2023-10-11 JP JP2023176130A patent/JP7840916B2/ja active Active
- 2023-11-13 US US18/507,167 patent/US12460017B2/en active Active
-
2025
- 2025-08-14 JP JP2025135273A patent/JP2025175286A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020536549A5 (https=) | ||
| JP2025102819A5 (https=) | ||
| JPWO2021155071A5 (https=) | ||
| JP2020516287A5 (https=) | ||
| JP2021520812A5 (https=) | ||
| JPWO2019200022A5 (https=) | ||
| Chen et al. | Bispecific antibodies in cancer immunotherapy | |
| JP2021502104A5 (https=) | ||
| JP2021534783A5 (https=) | ||
| JPWO2020135201A5 (https=) | ||
| US20160090426A1 (en) | Construction and application of bispecific antibody EpCAMxCD3 | |
| JP2019519492A5 (https=) | ||
| JP2025078629A5 (https=) | ||
| CN104592392B (zh) | 一种双特异性抗体EpCAM×CD3的构建及应用 | |
| JP2022553464A (ja) | 多重特異性抗体とその製造方法および使用 | |
| FI4034252T3 (fi) | Saranadomeenin sisältäviä Notch-reseptoreita | |
| RU2015102193A (ru) | Биспецифические асимметричные гетеродимеры, содержащие анти-cd3 конструкции | |
| CN103833852A (zh) | 针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体 | |
| HRP20190756T1 (hr) | Cd3-vezujuće molekule sposobne za vezanje za humani i nehumani cd3 | |
| WO2021185337A1 (zh) | 一种双特异性融合蛋白及其应用 | |
| JP2023159379A (ja) | Ｐｄ－１とｖｅｇｆを標的とした四価二重特異性抗体、その製造方法および用途 | |
| CN104592391A (zh) | 一种双特异性抗体EpCAM×CD3的构建及应用 | |
| CN113490690A (zh) | 异源二聚体融合蛋白 | |
| TW202334233A (zh) | 結合γδ T細胞之多肽及其用途 | |
| JPWO2023004304A5 (https=) |